A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4
CD4(+) T cell response
CP: Immunology
MHC-II antigenic presentation
antigen routing
intranasal immunization
lentiviral vectors
mucosal immunity
mycobacteria
polyantigen
polyfunctional T cells
tuberculosis
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
26 07 2022
26 07 2022
Historique:
received:
10
06
2021
revised:
11
05
2022
accepted:
07
06
2022
entrez:
29
7
2022
pubmed:
30
7
2022
medline:
3
8
2022
Statut:
ppublish
Résumé
Lentiviral vectors (LVs) are highly efficient at inducing CD8
Identifiants
pubmed: 35905717
pii: S2211-1247(22)00951-2
doi: 10.1016/j.celrep.2022.111142
pii:
doi:
Substances chimiques
Antigens, Bacterial
0
Antigens, Differentiation, B-Lymphocyte
0
Histocompatibility Antigens Class II
0
invariant chain
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111142Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests P.C. is the founder and CSO of TheraVectys. J.L., F.A., P.A., M.-W.K., F.M., and A.N. are employees of TheraVectys. J.L., F.A., C.B., F.M., L.M., and P.C. are inventors of a pending patent directed to LV immunization able to induce CD4(+) T cells.